Other formats:
BibTeX
LaTeX
RIS
@misc{838404,
author = {Guzi, Timothy and Paruch, Kamil and Dwyer, Michael and Doll, Ronald and Girijavallabhan, Viyyoor and Knutson, Chad and McKittrick, Brian and Dillard, Lawrence and Tran, Vinh and He, Zhen and James, Ray and Park, Haengsoon},
keywords = {cyclin dependent kinase; inhibitor; pyrazolopyrimidine},
language = {eng},
title = {Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors},
year = {2004}
}
TY - PAT
ID - 838404
AU - Guzi, Timothy - Paruch, Kamil - Dwyer, Michael - Doll, Ronald - Girijavallabhan, Viyyoor - Knutson, Chad - McKittrick, Brian - Dillard, Lawrence - Tran, Vinh - He, Zhen - James, Ray - Park, Haengsoon
PY - 2004
TI - Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors
KW - cyclin dependent kinase
KW - inhibitor
KW - pyrazolopyrimidine
N2 - The title pyrazolo[1,5-a]pyrimidines [I; Q = SO2NR6R7, CONR6R7, CO2R7; R2 = (un)substituted alkyl, alkynyl, alkynylalkyl, cycloalkyl, CF3, CO2R6, aryl, arylalkyl, heteroarylalkyl, heterocyclyl, etc., wherein aryl is optionally substituted; R3 = H, halogen, NR5R6, CONR5R6, CO2R4, each (un)substituted alkyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, etc.; R4 = H, halo, alkyl; R5 = H, alkyl; R6 = H, each (un)substituted alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl; R7 = each (un)substituted alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; or R5 and R6 in the moiety -NR5R6, may be joined together to form an (un)substituted cycloalkyl or heterocyclyl] or pharmaceutically acceptable salts or solvates thereof are prepd. In its many embodiments, the present invention also provides methods of prepg. such compds., pharmaceutical compns. contg. one or more such compds. I, methods of prepg. pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases assocd. with cyclin dependent kinase using such compds. I or pharmaceutical compns. The disease assocd. with cyclin dependent kinase is selected from the group consisting of; (1) cancer of the bladder, breast, colon, kidney, liver, lung, small cell lung cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; (2) leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkitt's lymphoma; (3) acute and chronic myelogenous leukemia, myelodysplastic syndrome and promyelocytic leukemia; (4) fibrosarcoma and rhabdomyosarcoma; (5) astrocytoma, neuroblastoma, glioma and schwannomas; and (6) melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoacanthoma, thyroid follicular cancer and Kaposi's sarcoma.
ER -
GUZI, Timothy, Kamil PARUCH, Michael DWYER, Ronald DOLL, Viyyoor GIRIJAVALLABHAN, Chad KNUTSON, Brian MCKITTRICK, Lawrence DILLARD, Vinh TRAN, Zhen HE, Ray JAMES and Haengsoon PARK. \textit{Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors}. 2004.
|
